22 min

Overview of efficacy and safety data of combination therapy with PARPi and NHAs COR2ED Medical Education

    • Science

Overview of efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented and the impact for the treatment of patients with mCRPC
COR2ED Medical Education: Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, University of Utah in the United States discuss the efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented at ASCO GU 2023 and the impact for the treatment of patients with mCRPC in this GU CONNECT podcast.
In this podcast, the experts discuss the updated survival analysis from the PROPEL study of olaparib and abiraterone which demonstrated a benefit in an all-comer mCRPC population and the second interim analysis from the MAGNITUDE study which showed a benefit of niraparib plus abiraterone in mCRPC patients with homologous recombination repair alterations. They also discuss the differing trial results and how these compare to the most recent data presented from the TALAPRO-2 trial of talazoparib plus enzalutamide which showed a benefit in a biomarker unselected population.
The experts consider how this combination therapy may be implemented in clinical practice in the future pending regulatory approval of the combinations.

Overview of efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented and the impact for the treatment of patients with mCRPC
COR2ED Medical Education: Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, University of Utah in the United States discuss the efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented at ASCO GU 2023 and the impact for the treatment of patients with mCRPC in this GU CONNECT podcast.
In this podcast, the experts discuss the updated survival analysis from the PROPEL study of olaparib and abiraterone which demonstrated a benefit in an all-comer mCRPC population and the second interim analysis from the MAGNITUDE study which showed a benefit of niraparib plus abiraterone in mCRPC patients with homologous recombination repair alterations. They also discuss the differing trial results and how these compare to the most recent data presented from the TALAPRO-2 trial of talazoparib plus enzalutamide which showed a benefit in a biomarker unselected population.
The experts consider how this combination therapy may be implemented in clinical practice in the future pending regulatory approval of the combinations.

22 min

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Radiolab
WNYC Studios
Making Sense with Sam Harris
Sam Harris
Ologies with Alie Ward
Alie Ward
StarTalk Radio
Neil deGrasse Tyson